Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced today a second commercial agreement with Weill Cornell Medicine to expand the use of its Nociscan platform in a groundbreaking clinical trial. The trial, led by renowned neurosurgeon Roger Härtl, MD, aims to evaluate the long-term effects of lumbar microdiscectomy surgery with and without an intradiscal bone marrow aspirate concentrate (BMAC) injection on patient outcomes, intervertebral disc health, and pain biomarkers.
The study, titled “Bone Marrow Aspirate Concentrate Injection with MRI’s – a Prospective Randomized Controlled Trial” (IRB Protocol No. 24-09027977), will follow patients over two years to better understand degenerative disc disease (DDD) and inform treatment strategies. Dr. Härtl, founder and director of the Weill Cornell Medicine Center for Comprehensive Spine Care and co-director of Och Spine at NewYork-Presbyterian, noted, “This trial strives to enhance our understanding of disc degeneration in patients, and illuminate chemical aspects of disc degeneration not available with traditional imaging.”
Nociscan is a SaaS platform that uses magnetic resonance spectroscopy data and proprietary augmented intelligence algorithms to noninvasively identify painful discs in the lumbar spine. It quantifies chemical biomarkers associated with disc pain and has demonstrated a 97% surgical success rate when all Nociscan-identified pain-positive discs are treated. This is the second trial at Weill Cornell to incorporate Nociscan, highlighting the growing recognition of its value in spine research.
Chronic low back pain affects approximately 266 million people worldwide, according to a study in Global Spine Journal. Ryan Bond, Chief Strategy Officer of Aclarion, emphasized the importance of this research: “Progressive trials such as this one are a clear example for how healthcare advances – investigating a major global health issue, like degenerative disc disease, while using innovative tools like Nociscan.”
The agreement marks a significant step for Aclarion as it continues to expand its commercial partnerships and clinical evidence base. For more information about Aclarion and Nociscan, visit www.aclarion.com or view the latest news at https://tinyurl.com/aconnewsroom.
